Molecular determinants of HIV-2 R5-X4 tropism in the V3 loop: Development of a new genotypic tool

Journal of Infectious Diseases

Volumn 205, Issue 1, 2012, Pages 111-120

  Visseaux, Benoit ^a,b   Hurtado Nedelec, Margarita ^a   Charpentier, Charlotte ^a,b   Collin, Gilles ^a,b   Storto, Alexandre ^a,b   Matheron, Sophie ^a,b   Larrouy, Lucile ^a,b   Damond, Florence ^a,b   Brun Vézinet, Franoise ^a,b   Descamps, Diane ^a,b  

^a BICHAT HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; GREEN FLUORESCENT PROTEIN;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; MAJOR CLINICAL STUDY; MONONUCLEAR CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOSARCOMA CELL; PHENOTYPE; PRIORITY JOURNAL; VIRAL TROPISM; VIRUS ISOLATION; VIRUS MUTATION; VIRUS STRAIN;

BASE SEQUENCE; CELL LINE, TUMOR; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENETIC ASSOCIATION STUDIES; GENOTYPING TECHNIQUES; HIV-2; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; RNA, VIRAL; SEQUENCE ANALYSIS, RNA; VIRAL TROPISM;

EID: 84555189229     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir698     Document Type: Article

References (39)

1. Valadas E, Francxa L, Sousa S, Antunes F. 20 years of HIV-2 infection in Portugal: trends and changes in epidemiology. Clin Infect Dis 2009; 48:1166-7.
2. Brunet S, Thierry D, Barin F, et al. Surveillance de l'infection à VIH-sida en France, 2007. BEH 2008; 45:434-42.
3. Roquebert B, Damond F, Collin G, et al. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J Antimicrob Chemother 2008; 62:914-20.
4. Ntemgwa ML, d'Aquin Toni T, Brenner BG, Camacho RJ, Wainberg MA. Antiretroviral drug resistance in human immunodeficiency virus type 2. Antimicrob Agents Chemother 2009; 53:3611-9.
5. Ren J, Bird LE, Chamberlain PP, Stewart-Jones GB, Stuart DI, Stammers DK. Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors. Proc Natl Acad Sci U.S.A 2002; 99:14410-5. (Pubitemid 35257685)
6. Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, HeneineW. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther 2004; 9:57-65. (Pubitemid 38313948)
7. Poveda E, Briz V, Soriano V. Enfuvirtide, the first fusion inhibitor to treat HIV infection. AIDS Rev 2005; 7:139-47. (Pubitemid 41671913)
8. Desbois D, Roquebert B, Peytavin G, et al. In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors. Antimicrob Agents Chemother 2008; 52:1545-8. (Pubitemid 351522031)
9. Willey S, Peters PJ, Sullivan WM, Dorr P, Perros M, Clapham PR. Inhibition of CCR5-mediated infection by diverse R5 and R5X4 HIV and SIV isolates using novel small molecule inhibitors of CCR5: effects of viral diversity, target cell and receptor density. Antiviral Res 2005; 68:96-108. (Pubitemid 41565524)
10. Armstrong-James D, Stebbing J, Scourfield A, et al. Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc. Antiviral Res 2010; 86:224-6.
11. Stegmann S, Manea ME, Charpentier C, et al. Foscarnet as salvage therapy in HIV-2-infected patient with antiretroviral treatment failure. J Clin Virol 2010; 47:79-81.
12. McKnight A, Dittmar MT, Moniz-Periera J, et al. A broad range of chemokine receptors are used by primary isolates of human immunodeficiency virus type 2 as coreceptors with CD4. J Virol 1998; 72:4065-71. (Pubitemid 28188711)
13. Mörner A, Björndal A, Leandersson A, Albert J, Björling E, Jansson M. CCR5 or CXCR4 is required for efficient infection of peripheral blood mononuclear cells by promiscuous human immunodeficiency virus type 2 primary isolates. AIDS Res Hum Retroviruses 2002; 18:193-200. (Pubitemid 34161238)
14. Guillon C, van der Ende ME, Boers PH, Gruters RA, Schutten M, Osterhaus AD. Coreceptor usage of human immunodeficiency virus type 2 primary isolates and biological clones is broad and does not correlate with their syncytium-inducing capacities. J Virol 1998; 72:6260-3. (Pubitemid 28283428)
15. Mörner A, Björndal A, Albert J, et al. Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J Virol 1999; 73:2343-9. (Pubitemid 29098139)
16. Owen SM, Ellenberger D, Rayfield M, et al. Genetically divergent strains of human immunodeficiency virus type 2 use multiple coreceptors for viral entry. J Virol 1998; 72:5425-32. (Pubitemid 28283323)
17. Shi Y, Brandin E, Vincic E, et al. Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylation. J Gen Virol 2005; 86:3385-96. (Pubitemid 41685173)
18. Blaak H, Boers PH, Gruters RA, Schuitemaker H, van der Ende ME, Osterhaus AD. CCR5, GPR15, and CXCR6 are major coreceptors of human immunodeficiency virus type 2 variants isolated fromindividuals with and without plasma viremia. J Virol 2005; 79:1686-700. (Pubitemid 40459115)
19. Zhang Y, Lou B, Lal RB, Gettie A, Marx PA, Moore JP. Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells. J Virol 2000; 74:6893-10.
20. Kuhmann SE, Hartley O. Targeting chemokine receptors in HIV: a status report. Annu Rev Pharmacol Toxicol 2008; 48:425-61. (Pubitemid 351738160)
21. Tsibris AM, Kuritzkes DR. Chemokine antagonists as therapeutics: focus on HIV-1. Annu Rev Med 2007; 58:445-59. (Pubitemid 46706526)
22. Whitcomb JM, Huang W, Fransen S, et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 2007; 51:566-75. (Pubitemid 46185274)
23. Jensen MA, van 't Wout AB. Predicting HIV-1 coreceptor usage with sequence analysis. AIDS Rev 2003; 5:104-12. (Pubitemid 36873899)
24. Beerenwinkel N, Sing T, Lengauer T, et al. Computational methods for the design of effective therapies against drug resistant HIV strains. Bioinformatics 2005; 21:3943-50. (Pubitemid 41631832)
25. Web PSSM. http://indra.mullins.microbiol.washington.edu/webpssm/index. html. Accessed 10 March 2011.
26. Geno2pheno coreceptor. http://coreceptor.bioinf.mpi-inf.mpg.de/index.php. Accessed 10 March 2011.
27. Skrabal K, Low AJ, Dong W, et al. Determining human immunodeficiency virus coreceptor use in a clinical setting: degree of correlation between two phenotypic assays and a bioinformatic model. J Clin Microbiol 2007; 45:279-84.
28. Raymond S, Delobel P, Mavigner M, et al. Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism. AIDS 2008; 22:F11-6.
29. Albert J, Sta°lhandske P, Marquina S, et al. Biological phenotype of HIV type 2 isolates correlates with V3 genotype. AIDS Res Hum Retroviruses 1996; 12:821-8. (Pubitemid 26171123)
30. Isaka Y, Sato A, Miki S, et al. Small amino acid changes in the V3 loop of human immunodeficiency virus type 2 determines the coreceptor usage for CXCR4 and CCR5. Virology 1999; 264:237-43. (Pubitemid 29531906)
31. Kulkarni S, Tripathy S, Agnihotri K, et al. Indian primary HIV-2 isolates and relationship between V3 genotype, biological phenotype and coreceptor usage. Virology 2005; 337:68-75. (Pubitemid 40725440)
32. Davis HE, Rosinski M, Morgan JR, Yarmush ML. Charged polymers modulate retrovirus transduction via membrane charge neutralization and virus aggregation. Biophys J 2004; 86:1234-42. (Pubitemid 38209565)
33. Ho WZ, Cherukuri R, Ge SD, et al. Centrifugal enhancement of human immunodeficiency virus type 1 infection and human cytomegalovirus gene expression in human primary monocyte/macrophages in vitro. J Leukoc Biol 1993; 53:208-12. (Pubitemid 23100165)
34. Pietroboni GR, Harnett GB, Bucens MR. Centrifugal enhancement of human immunodeficiency virus (HIV) and human herpesvirus type 6 (HHV-6) infection in vitro. J Virol Methods 1989; 24:85-90. (Pubitemid 19134883)
35. Vödrös D, Tscherning-Casper C, Navea L, Schols D, De Clercq E, Fenyö EM. Quantitative evaluation of HIV-1 coreceptor use in the GHOST3 cell assay. Virology 2001; 291:1-11. (Pubitemid 34062195)
36. Cho MW, Lee MK, Carney MC, Berson JF, Doms RW, Martin MA. Identification of determinants on a dualtropic human immunodeficiency virus type 1 envelope glycoprotein that confer usage of CXCR4. J Virol 1998; 72:2509-15. (Pubitemid 28100815)
37. Schols D, Esté JA, Cabrera C, De Clercq E. T-cell-line-tropic human immunodeficiency virus type 1 that is made resistant to stromal cellderived factor 1alpha contains mutations in the envelope gp120 but does not show a switch in coreceptor use. J Virol 1998; 72:4032-7. (Pubitemid 28188707)
38. Recordon-Pinson P, Soulié C, Flandre P, et al. Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study. Antimicrob Agents Chemother 2010; 54:3335-40.
39. McGovern RA, Thielen A, Mo T, et al. Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies. AIDS 2010; 24:2517-25.